Immunophotonicsincis A Clinical Stage Biotech Company Based In Stlouismissourifounded In 2008The Company Specializes In Interventional Immuno Oncologyfocusing On Developing Innovative Treatments For Cancerparticularly Addressing Tumor Recurrence After Initial Therapies The Primary Product Of Immunophotonics Is Ip 001A Proprietary Glycan Polymer Designed To Stimulate A Tumor Specific Adaptive Immune Responsethis Drug Targets Micrometastaseswhich Are Small Cancer Cells That Can Lead To Disease Progressionip 001 Works By Leveraging Tumor Associated Antigens Released During First Line Locoregional Therapies To Enhance The Body S Immune Response Against Cancer Cells Immunophotonics Is Conducting Phase 1B 2A Clinical Trials For Ip 001 In Several Countriesincluding The United States And Parts Of Europethese Trials Focus On Advanced Cancer Patients And Have Shown Promising Resultsindicating A Favorable Toxicity Profile And Early Signs Of Systemic Anti Tumor Immune Responsesthe Company S Approach Aims To Improve T Cell Trafficking And Demonstrate Anti Tumor Activity While Maintaining Existing Clinical Workflows
United States
